# Study of Pembrolizumab in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine: Integration of Molecular Subtypes Through Integrative Genomic Analysis

> **NCT02589496** · PHASE2 · COMPLETED · sponsor: **Samsung Medical Center** · enrollment: 80 (actual)

## Conditions studied

- Gastric Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma

## Interventions

- **DRUG:** pembrolizumab

## Key facts

- **NCT ID:** NCT02589496
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-26
- **Primary completion:** 2021-12
- **Final completion:** 2021-12
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2023-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02589496

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02589496, "Study of Pembrolizumab in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine: Integration of Molecular Subtypes Through Integrative Genomic Analysis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02589496. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*